Oblean (Obesity) - Forecast and Market Analysis to 2022


Naperville, IL -- (SBWIRE) -- 03/24/2014 -- Reportstack, provider of premium market research reports announces the addition of Oblean (Obesity) - Forecast and Market Analysis to 2022 market report to its offering
Oblean (Obesity) - Forecast and Market Analysis to 2022


After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Norgine and Takedas Oblean (cetilistat) received Japanese regulatory approval for the treatment of obesity with complications in September 2013, less than one year after the NDA was submitted to the Ministry of Health, Labour and Welfare (MHLW). This compound was originally developed by UK-based Alizyme Therapeutics Limited and was acquired by Norgine in October 2009. Oblean has comparable efficacy to Xenical in inducing weight loss, but with a more favorable gastrointestinal side effect profile


- Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Oblean including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Oblean for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil, Japan and Canada

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for obesity.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Oblean performance
- Obtain sales forecast for Oblean from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, China, Brazil, Japan and Canada)

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604